Clinical Trials Logo

Filter by:
NCT ID: NCT04414904 Withdrawn - Infertility, Male Clinical Trials

Determining the Reproductive Health of Men Post-COVID-19 Infection

Start date: June 10, 2020
Phase:
Study type: Observational

Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.

NCT ID: NCT04399733 Withdrawn - Health Disparities Clinical Trials

EMPOWER - BAME vs COVID

Start date: February 1, 2021
Phase:
Study type: Observational

The COVID-19 virus pandemic has massively affected us all. Moreover, there is a disproportionately high number of COVID-19 severe infections and deaths in British Black, Asian and minority ethnic (BAME) patients. This clinical study plans to discover new ways of protecting people from this virus by looking at our DNA and biology.

NCT ID: NCT04395976 Withdrawn - Covid-19 Clinical Trials

Ayurveda as Prophylaxis for Suspected COVID-19 Patients

Start date: May 10, 2020
Phase: N/A
Study type: Interventional

Despite worldwide efforts to contain, manage and treat Covid-19, the pandemic is continuing to spread. This calls for an urgent clinically-proven prophylaxis and therapeutic strategy. Recent developments on the use of traditional medicines in Covid-19 management has drawn enough attention to start several research studies. Based on the Indian Traditional Medicine, Ayurveda's community initiatives, preliminary studies, and our experiential knowledge on Covid-19 settings, we propose present study to prevent the development of COVID-19 symptoms in people who live or have come contact with an individual diagnosed with COVID-19.

NCT ID: NCT04391673 Withdrawn - Vestibular Disease Clinical Trials

Factors Affecting Outcome of Vestibular Rehabilitation

Start date: September 26, 2019
Phase:
Study type: Observational

This is an observational longitudinal study to investigate if negative illness perceptions predict less improvement in dizziness handicap following vestibular rehabilitation. Consecutive patients (n=260) who enter the vestibular rehabilitation programme at Guy's Hospital, London will be included. Questionnaires will be conducted immediately before, and after their final treatment. The main outcome will be the Dizziness Handicap Inventory after rehabilitation.

NCT ID: NCT04389229 Withdrawn - Clinical trials for Ovarian Cancer Metastatic

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

OVSTAR
Start date: July 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

An open label, multi-centre Phase 1/2a study of modified and unmodified autologous Tumour Infiltrating Lymphocytes (TIL) in patients with platinum-resistant ovarian cancer. The purpose of this phase I/II study is to evaluate the feasibility and safety of both standard unmodified TIL (UTIL-01) and TIL engineered to express the co-stimulatory receptor CoStAR (CoTIL-01) in platinum resistant ovarian cancer.

NCT ID: NCT04369157 Withdrawn - Clinical trials for Cognitive Dysfunction

Zinc and Post-Operative Cognitive Dysfunction

Start date: January 1, 2021
Phase:
Study type: Observational

A decline in cognitive abilities following surgery (POCD: Post-Operative Cognitive Dysfunction) affects up to 47% of patients undergoing a surgical procedure. Risk factors include age, previous depression, alcohol and drug use, smoking, cognitive impairment as well as pre-operative biochemical and haematological abnormalities. Inflammation has been proposed as a potential cause, however, there is little empirical and clinical evidence in this area to determine aetiology or reduce risk of incidence. Zinc is an important metal for brain function, with deficiency associated with poorer cognitive outcomes. In relation to POCD, biomarker studies have revealed that levels of a zinc-alpha-2-glycoprotein (AZGP1) were lower in patients with POCD. AZGP1 is a multifunctional glycoprotein implicated in cell adhesion, immune response, transmembrane transport and cellular proliferation. Microglia, the immune cells of the brain, are highly sensitive to changes in zinc which have been proposed to contribute to neurodegenerative disease as well as POCD. However, whilst animal studies looking at the effects of zinc on cognition have been promising, robust human trials are lacking. This research aims to establish the role of zinc in POCD by determining associations between zinc status, inflammation, cognitive function, and biomarkers of POCD risk and incidence. This will be achieved by gathering clinical and cognitive data from a sample of older adults undergoing surgery. Blood samples will be taken pre and post-operatively to establish zinc status and plasma concentrations of biomarkers of POCD risk and incidence. Pre and post-operative cognitive assessments will also be conducted to measure memory and executive function. Incidence of POCD will be determined via neurological assessment according to diagnostic criteria. Should associations between zinc status, POCD biomarkers, inflammation, cognitive performance and POCD incidence be established, not only would it lead to future work to investigate potential mechanisms of action as well as intervention studies looking to support zinc status, optimising early identification of individuals who may be at higher risk of developing POCD should lead to better patient outcomes.

NCT ID: NCT04363372 Withdrawn - COVID-19 Clinical Trials

A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19

Start date: August 2020
Phase: Phase 2
Study type: Interventional

This is a randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of MRx-4DP0004 in patients with COVID-19. 90 hospitalised patients will be enrolled and randomised (2:1) to receive MRx-4DP0004 or placebo for up to 14 days. MRx-4DP0004 is an immunomodulating Live Biotherapeutic Product (LBP) which is expected to prevent or reduce the hyperinflammatory response to SARS-CoV-2 infection without impairing viral clearance.

NCT ID: NCT04340921 Withdrawn - COVID Clinical Trials

The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury

Start date: May 14, 2020
Phase:
Study type: Observational

COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.

NCT ID: NCT04335565 Withdrawn - Obesity Clinical Trials

Stevia Extract and Glucose Homeostasis

Start date: March 3, 2020
Phase: N/A
Study type: Interventional

This study aims to assess the effect of stevia extract on postprandial glucose and insulin levels in overweight and obese adults when compared to sugar and water.

NCT ID: NCT04334629 Withdrawn - Coronavirus Clinical Trials

LIBERATE Trial in COVID-19

LIBERATE
Start date: May 26, 2020
Phase: Phase 4
Study type: Interventional

The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.